129 related articles for article (PubMed ID: 36990320)
1. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study.
Fujimoto T; Terahara T; Okawa K; Inakura H; Hirayama Y; Yokozeki H
J Am Acad Dermatol; 2023 Jul; 89(1):62-69. PubMed ID: 36990320
[TBL] [Abstract][Full Text] [Related]
2. Long-term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open-label extension study.
Fujimoto T; Terahara T; Okawa K; Inakura H; Hirayama Y; Yokozeki H
J Dermatol; 2023 Nov; 50(11):1459-1472. PubMed ID: 37605375
[TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis.
Wolosker N; de Campos JR; Kauffman P; Puech-Leão P
J Vasc Surg; 2012 Jun; 55(6):1696-700. PubMed ID: 22341836
[TBL] [Abstract][Full Text] [Related]
4. Oxybutynin gel versus nanoemulgel for treating primary palmar hyperhidrosis: A pilot double-blind randomized controlled trial.
Saki N; Shakouri N; Rastaghi F; Hosseini SA; Alipour S; Ahramiyanpour N
J Cosmet Dermatol; 2023 Aug; 22(8):2268-2272. PubMed ID: 36999480
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study.
Campanati A; Gregoriou S; Consales V; Rizzetto G; Bobyr I; Diotallevi F; Martina E; Kontochristopoulos G; Platsidaki E; Offidani A
Dermatol Ther; 2020 Nov; 33(6):e14039. PubMed ID: 32691938
[TBL] [Abstract][Full Text] [Related]
6. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial.
Schollhammer M; Brenaut E; Menard-Andivot N; Pillette-Delarue M; Zagnoli A; Chassain-Le Lay M; Sassolas B; Jouan N; Le Ru Y; Abasq-Thomas C; Greco M; Penven K; Roguedas-Contios AM; Dupré-Goetghebeur D; Gouedard C; Misery L; Le Gal G
Br J Dermatol; 2015 Nov; 173(5):1163-8. PubMed ID: 26114588
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy of THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects With Primary Focal Hyperhidrosis.
Pariser DM; Krishnaraja J; Tremblay TM; Rubison RM; Love TW; McGraw BF
J Drugs Dermatol; 2017 Feb; 16(2):127-132. PubMed ID: 28300854
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of methantheline bromide (Vagantin(®) ) in axillary and palmar hyperhidrosis: results from a multicenter, randomized, placebo-controlled trial.
Müller C; Berensmeier A; Hamm H; Dirschka T; Reich K; Fischer T; Rzany B
J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1278-84. PubMed ID: 23004926
[TBL] [Abstract][Full Text] [Related]
9. Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study.
Artzi O; Loizides C; Zur E; Sprecher E
Acta Derm Venereol; 2017 Oct; 97(9):1120-1124. PubMed ID: 28654131
[TBL] [Abstract][Full Text] [Related]
10. [Use of oral oxybutynin at 7.5 mg per day in primary hyperhidrosis].
Try C; Messikh R; Elkhyat A; Aubin F; Humbert RP
Rev Med Liege; 2012 Oct; 67(10):520-6. PubMed ID: 23167161
[TBL] [Abstract][Full Text] [Related]
11. [Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis].
Hund M; Sinkgraven R; Rzany B
J Dtsch Dermatol Ges; 2004 May; 2(5):343-9. PubMed ID: 16281522
[TBL] [Abstract][Full Text] [Related]
12. An alternative to treat palmar hyperhidrosis: use of oxybutynin.
Wolosker N; de Campos JR; Kauffman P; Neves S; Yazbek G; Jatene FB; Puech-Leão P
Clin Auton Res; 2011 Dec; 21(6):389-93. PubMed ID: 21688168
[TBL] [Abstract][Full Text] [Related]
13. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok R; Drew J; Quiring J; Pariser DM
J Am Acad Dermatol; 2019 Jan; 80(1):128-138.e2. PubMed ID: 30003988
[TBL] [Abstract][Full Text] [Related]
14. A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis.
Glaser DA; Hebert AA; Nast A; Werschler WP; Green L; Mamelok RD; Quiring J; Drew J; Pariser DM
Am J Clin Dermatol; 2019 Aug; 20(4):593-604. PubMed ID: 31111409
[TBL] [Abstract][Full Text] [Related]
15. Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis.
Wolosker N; Krutman M; Teivelis MP; Campbell TP; Kauffman P; de Campos JR; Puech-Leão P
Ann Vasc Surg; 2014 May; 28(4):970-6. PubMed ID: 24333527
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of the treatment of primary hyperhidrosis with oxybutynin: follow-up of 1,658 cases.
Wolosker N; Kauffman P; de Campos JRM; Faustino CB; da Silva MFA; Teivelis MP; Puech-Leão P
Int J Dermatol; 2020 Jun; 59(6):709-715. PubMed ID: 32301117
[TBL] [Abstract][Full Text] [Related]
17. Oxybutynin in primary hyperhidrosis: A long-term real-life study.
Almeida ART; Ferrari F; Restrepo MVS; Rocha VB
Dermatol Ther; 2020 Nov; 33(6):e14344. PubMed ID: 32981151
[TBL] [Abstract][Full Text] [Related]
18. Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.
Pariser DM; Hebert AA; Drew J; Quiring J; Gopalan R; Glaser DA
Am J Clin Dermatol; 2019 Feb; 20(1):135-145. PubMed ID: 30378087
[TBL] [Abstract][Full Text] [Related]
19. Oxybutynin 3% gel for the treatment of primary focal hyperhidrosis in adolescents and young adults.
Nguyen NV; Gralla J; Abbott J; Bruckner AL
Pediatr Dermatol; 2018 Mar; 35(2):208-212. PubMed ID: 29334132
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis.
Baumann L; Slezinger A; Halem M; Vujevich J; Mallin K; Charles C; Martin LK; Black L; Bryde J
Dermatol Surg; 2005 Mar; 31(3):263-70. PubMed ID: 15841624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
